$PSNL

Tachibana Aaron sold $480K of PSNL

Tachibana Aaron (CFO AND COO) sold 40,000 shares of Personalis, Inc. (PSNL) at $12.01 ($0.48M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tachibana Aaron
Published Jun 6, 2026, 12:19 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 6, 2026, 12:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PSNL
Neutral
medium confidence
Mentioned
$PSNL
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PSNLNeutralLow
01

Why it matters

The disclosure provides a measurable insider behavior datapoint (40,000 shares at $12.0100) but does not, by itself, establish a new fundamental driver.

02

Market read

For PSNL, this is a sentiment/positioning input rather than a catalyst; any trading impact is likely small and short-lived.

03

What to watch

Traders may over-weight the sale without checking whether other insiders/funds simultaneously bought or whether the company has upcoming catalysts (earnings, trial updates) not mentioned here.

Relevance 6/10Novelty 6/10Timing: Filed June 5; sale executed June 4 (after-hours/next-session read-through).

Background

SEC Form 4 reports an officer’s transaction in the issuer’s own shares; 10b5-1 indicates the trade was pre-scheduled under SEC rules.

Company-level read

Ticker impact

$PSNLNeutralMedium confidence
Context

Personalis CFO/COO Tachibana Aaron sold 40,000 PSNL shares for ~$480.4K under a pre-arranged 10b5-1 plan, per SEC Form 4.

Expected impact

Low-to-moderate short-term downside bias possible, but impact likely muted versus non-10b5-1 sales.

Evidence & confidence

The filing is a concrete datapoint (sale size, price, date) but explicitly tied to a pre-arranged 10b5-1 plan, reducing interpretive weight.

Market effects

Limited sector read-through; this is company-specific insider activity with no stated operational/regulatory catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity needs rather than negative fundamentals; price reaction could be overstated.

Key entities

  • Personalis, Inc.

    US-listed company (PSNL) whose officer sold shares disclosed in SEC Form 4.

  • Tachibana Aaron

    CFO and COO who executed an open-market sale under a pre-arranged 10b5-1 plan.

Related articles

$PSNLMed

Personalis Reports Second Quarter 2026 Results and Recent Highlights

Personalis (Nasdaq: PSNL) reported Q2 2026 results for the quarter ended June 30. Clinical tests rose 199% to 10,384. Clinical revenue increased 442% to $2.6 million, while total revenue grew 30% to $22.4 million. The company said it secured Medicare coverage for NeXT Personal in additional IO and neoadjuvant breast cancer indications and ended the quarter with about $212.7 million in cash.

$PSNLMedAI 8/10

Personalis, Inc. (PSNL): Results of Operations and Financial Condition

Personalis, Inc. (PSNL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 psnl-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Personalis Reports Second Quarter Results and Recent Highlights Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2 Clinical revenue grew 442% to $2.6 million and overall revenue grew 30

$TEMMedAI 8/10

Dear Tempus AI Stock Fans, Mark Your Calendars for July 30

Tempus AI (NASDAQ: TEM) agreed to acquire Personalis (PSNL) for $16.25 per share in stock, valuing the deal at about $1.5 billion enterprise value net of Tempus’ existing stake, with closing expected late 2026 or early 2027. Tempus expects integration to expand MRD capabilities. After the July 20 announcement, TEM fell 7.74% intraday. In Q1, revenue rose 36.1% to $348.12M. Needham reiterated Buy at $75; consensus target is $66.75.

$TEMMedAI 8/10

Tempus makes $1.5B bet to corner cancer-test market

Tempus AI (TEM) agreed to acquire Personalis (PSNL) for about $1.5 billion, paying $16.25 per Personalis share including debt. The deal gives Tempus full control of the NeXT Personal MRD cancer test. Personalis reported preliminary Q2 revenue of $22.4 million. Tempus stock fell about 9% on July 20 amid expected dilution and delayed closing to late 2026/early 2027.

$TEMMedAI 8/10

Dollar Bet on the Future of Cancer Monitoring

Tempus AI (NASDAQ:TEM) agreed to acquire Personalis (NASDAQ:PSNL) for $1.5 billion to expand minimal residual disease (MRD) capabilities. Tempus shares recovered after an early selloff. William Blair sees strategic fit and a $20 billion MRD market, but notes a high ~14x 2027 sales multiple and Personalis’ expected 2027 adjusted EBITDA loss of about $90 million. BNP Paribas said the deal could increase pressure on Natera (NASDAQ:NTRA).